Related Experiment Video

Updated: Jul 20, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

PEDF: a potential molecular therapeutic target with multiple anti-cancer activities

Eugene T H Ek1, Crispin R Dass, Peter F M Choong

  • 1Department of Orthopaedics, University of Melbourne St. Vincent's Hospital, Melbourne, PO Box 2900, Fitzroy, Melbourne, Australia.

Trends in Molecular Medicine
|September 12, 2006
PubMed

Insights

Pigment epithelium-derived factor (PEDF) shows promise as an anti-tumor agent by inhibiting tumor growth and blood vessel formation. Further research is needed to evaluate PEDF therapy

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Pigment epithelium-derived factor (PEDF) is an endogenous protein with diverse biological functions.
  • PEDF is recognized for its potent anti-angiogenic properties.
  • Emerging evidence suggests PEDF possesses anti-tumor capabilities.

Purpose of the Study:

  • To investigate the anti-tumor properties of PEDF.
  • To elucidate PEDF's role in anti-angiogenesis, anti-proliferation, and differentiation.
  • To assess the therapeutic potential of PEDF for cancer treatment.

Main Methods:

  • Review of existing literature on PEDF's biological activities.
  • Analysis of studies demonstrating PEDF's effects on tumor growth and angiogenesis.
  • Exploration of PEDF's impact on cellular proliferation and differentiation.

Main Results:

  • PEDF exhibits significant anti-angiogenic activity, crucial for tumor suppression.
  • PEDF demonstrates direct and indirect tumor suppressive effects.
  • PEDF acts as an anti-proliferative and pro-differentiation factor in tumor models.

Conclusions:

  • PEDF possesses multifaceted anti-tumor properties, including anti-angiogenesis, anti-proliferation, and pro-differentiation.
  • PEDF represents a promising candidate for novel cancer therapies.
  • Further investigation into PEDF delivery, stability, and toxicity is warranted for clinical translation.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: